Sergi Velasco Vila Bachelor’s degree in Biotechnology by Universitat Politècnica de Valencia, with a strong commitment to oncological research. My thesis project combines the development of oncological models with the research and development of new radiopharmaceuticals for the imaging-based diagnosis and treatment of various tumors using radioactive isotopes. Passionate about translational research and the impact of biotechnology in personalized medicine. Instituciones de las que forman parte Investigador predoctoral Imagen Médica Molecular Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Sergi Velasco Vila LinkedIn Twitter Orcid Instituciones de las que forman parte Investigador predoctoral Imagen Médica Molecular Vall Hebron Institut de Recerca Bachelor’s degree in Biotechnology by Universitat Politècnica de Valencia, with a strong commitment to oncological research. My thesis project combines the development of oncological models with the research and development of new radiopharmaceuticals for the imaging-based diagnosis and treatment of various tumors using radioactive isotopes. Passionate about translational research and the impact of biotechnology in personalized medicine.
I completed a Master's in Molecular Biomedicine at the Universidad Autónoma de Madrid. For two years, I worked at the Spanish National Cancer Research Centre (CNIO) in Madrid, conducting basic and translational research in the field of breast cancer. I also completed a training stay at the Spanish National Centre for Cardiovascular Research (CNIC) in Madrid to study the role of metabolism in breast cancer development. Subsequently, I worked at the University of Miami (United States) under the supervision of Professor Ralf Paus. By the end of 2023, I joined the Medical Imaging group at VHIR, led by Dr. Raul Herance, to pursue my doctoral thesis. My project focuses on developing new radiopharmaceuticals for personalized diagnosis using PET/CT technology, as well as treatment with radioactive isotopes for various pediatric and adult tumors.
Proyectos Resistencia a la insulina en la diabetes tipo 2: clarificando el mecanismo patogénico de la resistencia a la insulina miocárdica y los efectos de tratamientos con GLP-1 RA y SGLT2i IP: José Raul Herance Camacho Colaboradores: Sofia Rodriguez Fernandez, Sergi Velasco Vila, Clara Ramírez Serra, Azahara Maria Palomar Muñoz, Cristina Gamez Cenzano, Jana Vidal Otero, Carolina Aparicio Gomez, Alberto Roque Pérez, Queralt Martin Saladich, Julia Baguña Torres, Mercè Abad Martín, Olga Simó Servat, Pedro Alejandro Gil Millán, Maria Nazarena Pizzi, Emily Betancourt Fernández, Enrique Franky Vargas, Eser Ucar, Martha Sahylí Ortega Pijeira Entidad financiadora: Instituto de Salud Carlos III Financiación: 252500 Referencia: PI24/01356 Duración: 01/01/2025 - 31/12/2027 InmunoPET: radiofármacos de diagnóstico in vivo en cáncer IP: José Raul Herance Camacho Colaboradores: Laia Perez Lasarte, Sergi Velasco Vila Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 37800 Referencia: AGAUR/DI2023_3/00124 Duración: 01/03/2024 - 28/02/2027
